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Background: Schizophrenia and bipolar disorder share
aspects of phenomenology and neurobiology and thus
may represent a continuum of disease. Few studies have
compared connectivity across the brain in these disorders
or investigated their functional correlates. Methods: We
used resting-state functional magnetic resonance imaging
to evaluate global and regional connectivity in 32 healthy
controls, 19 patients with bipolar disorder, and 18 schizophrenia patients. Patients also received comprehensive neuropsychological and clinical assessments. We computed
correlation matrices among 266 regions of interest within
the brain, with the primary dependent measure being overall global connectivity strength of each region with every
other region. Results: Patients with schizophrenia had significantly lower global connectivity compared with healthy
controls, whereas patients with bipolar disorder had global
connectivity intermediate to and significantly different from
those of patients with schizophrenia and healthy controls.
Post hoc analyses revealed that compared with healthy controls, both patient groups had significantly lower connectivity in the paracingulate gyrus and right thalamus. Patients
with schizophrenia also had significantly lower connectivity in the temporal occipital fusiform cortex, left caudate
nucleus, and left thalamus compared with healthy controls.
There were no significant differences among the patient
groups in any of these regions. Lower global connectivity
among all patients was associated with worse neuropsychological and clinical functioning, but these effects were not
specific to any patient group. Conclusions: These findings
are consistent with the hypothesis that schizophrenia and
bipolar disorder may represent a continuum of global disconnectivity in the brain but that regional functional specificity may not be evident.

Key words: resting-state fMRI/schizophrenia/bipolar
disorder/connectivity
Introduction
Since the time of Kraeplin,1 a dichotomy between schizophrenia (SCZ) and bipolar disorder (BD) has been emphasized,
which continues today in the nosology of the Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV).2 There is increasing evidence, however, that
these disorders share similar epidemiologic features such
as incidence3 and genetic risk.4 Moreover, several risk genes
may be common to both disorders, including Disrupted in
Schizophrenia 1,5,6 neuregulin 1,7,8 catechol-o-methyl transferase,9 and the G72/G30 loci.10 Recent genome-wide association studies also report overlap in the genes implicated in
both disorders.11,12 Similarly, several studies reported familybased evidence in genetic overlap of these disorders.4
In vivo magnetic resonance imaging (MRI) studies
have provided information regarding the potential
overlap and the distinct brain regions that contribute to
the neurobiology of these disorders. For instance, there
is some evidence that gray matter structural alterations
within the thalamus13 and medial prefrontal cortex14
may be common to both disorders. Other data, however,
suggest that frontotemporal cortical abnormalities may
be unique to SCZ,15 whereas BD may be characterized
by disturbances in regions responsible for emotional
processing, including the orbital–frontal16 cortex. Along
these lines, a meta-analysis of volumetric brain-imaging
studies17 reported that compared with patients with SCZ,
patients with BD had larger amygdala volumes, thus
supporting the hypothesis that the neurobiology of BD
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may be characterized by abnormalities in regions critical
to emotional processing.
Functional MRI (fMRI) has provided additional
insights into the overlapping and distinct patterns of
brain connectivity that contribute to these disorders. In
a recent review, Whalley and colleagues18 reported that
among 21 studies, there was evidence for overactivation
in the medial temporal lobe in patients with BD compared with patients with SCZ on emotion or memory
tasks. Using functional network analysis to assess differential connectivity in resting-state networks in patients
with SCZ and those with psychotic BD and healthy subjects, Meda et al19 found unique patterns of connectivity
specific to SCZ (meso/paralimbic to sensory–motor) and
BD (meso/paralimbic to frontotemporal/paralimbic).
Chai et al20 reported that resting-state activities between
the medial prefrontal cortex and insula and between the
medial prefrontal cortex and ventrolateral prefrontal
cortex were positively correlated in BD, whereas patients
with SCZ did not demonstrate any resting-state associations between these regions.
Functional connectivity measures are being used
increasingly to distinguish patients with psychiatric disorders by focusing on deficits in global and local connectivity.21 This approach has been utilized most often in studies
of SCZ.22–26 For instance, van den Heuvel et al27 reported
evidence that patients with SCZ demonstrate less wellintegrated global connectivity such that the frontal hubs
play a less central role. Similarly, Cole et al28 reported
that global disconnectivity may contribute to prefrontal
cortical abnormalities in patients with SCZ. Moreover,
Venkataraman et al29 reported that less parietotemporal
connectivity correlated with positive symptoms in SCZ,
whereas greater connectivity in the frontoparietal circuit
was correlated with worse negative symptoms, suggesting
that different brain circuits may mediate aspects of phenomenology. In contrast, functional connectivity studies
in BD have not emphasized the investigation of global
connectivity patterns.

We examined patterns of connectivity using restingstate fMRI across the entire brain in 266 predefined
regions of interest (ROIs), encompassing cortical and
subcortical regions, to investigate similarities and differences in global and regional connectivities in patients
with SCZ and BD and in healthy controls (HCs). We also
examined the functional correlates of these connectivity
patterns. We hypothesized that patients with SCZ would
be characterized by the greatest pattern of global disconnectivity across the entire brain and that patients with BD
would demonstrate a pattern of disconnectivity intermediate to that in HCs and patients with SCZ.
Methods
Subjects
The study included 19 patients with BD, 18 SCZ patients,
and 32 HCs (see table 1). All subjects provided written
informed consent and the protocol was approved by the
Institutional Review Board of the North Shore–Long
Island Jewish Health System. Patients and HCs were
assessed using the Structured Clinical Interview for
DSM-IV2 Axis I Disorders (SCID). Patient diagnoses
were determined through consensus among 3 senior clinicians and confidence in the accuracy of the agreed-upon
diagnosis was assigned on a scale of 1–4 (4 denotes highest confidence). Patients with diagnoses assigned a high
confidence (3 or 4) were included in the current study. In
addition, HCs had no history of an Axis I disorder, as
determined from the nonpatient edition SCID-NP. Most
BD patients were of the psychotic subtype (16 of 19 had
a history of psychosis). The average disease duration was
20.80 ± 9.67 years in SCZ and 14.76 ± 9.43 years in BD
(in BD, disease duration information was available for
only 9 patients). Subjects were also evaluated with the
Brief Psychiatric Rating Scale (BPRS) and the Hamilton
Rating Scale for Depression (HRSD; 17-item scale). In
addition, BD patients were assessed using the ClinicianAdministered Rating Scale for Mania (CARS-M).

Table 1. Sample Characteristics and Psychotropic Medications at the Time of Scan

N (M/F)

Age ± SD (Age of
Onset ± SD)

HC: 32
43.6 ± 8.2
(20/12)
BD: 19
40.6 ± 13.3
(11/8) (24.1 ± 9.4)
SCZ: 18
45.0 ± 10.9
(13/5) (25.3 ± 6.1)

BPRS-18

HRSD-17 CARS-M

Antipsychotics
(Chlorpromazine
Equivalent)

—

—

—

—

25.7 ± 5.0

5.6 ± 4.4

31.3 ± 5.4

7.9 ± 4.4

5.25 ± 6.50 11/19
5/19
(228 ± 275 mg/d)
—
17/18
3/18
(664 ± 535 mg/d)

GABA
Agonists

Mood
Benztropine Stabilizers Lithium

—

—

—

—

1/19

4/19

4/19

7/18

5/18

0/18

Note: BPRS, Brief Psychiatric Rating Scale; HRSD, the Hamilton Rating Scale for Depression (17-item scale); CARS-M, ClinicianAdministered Rating Scale for Mania; GABA, gamma amino butyric acid; HC, healthy control; BD, bipolar disorder patients; SCZ,
schizophrenia patients. Antipsychotics included haloperidol, fluphenazine, asenapine, risperidone, quetiapine, olanzapine, ziprasidone,
aripiprazole, clozapine. GABA agonists included clonazepam, alprazolam, lorazepam, zolpidem. Mood stabilizers included valproate,
carbamazepine, lamotrigine, topiramate.
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Average symptom scores for the SCZ and BD groups
for these scales and the medication information are provided in table 1. None of the HCs was receiving psychotropic medication. All patients were administered the
MATRICS Consensus Cognitive Battery (MCCB).30,31
Further details regarding this battery are provided in the
supplementary data.
Resting-State fMRI Image Acquisition
MRI examinations were conducted on a 3T scanner
(GE Signa HDx). For image registration, we acquired
anatomical scans in the coronal plane using an
inversion-recovery-prepared 3-dimensional (3D) fast
spoiled gradient (IR-FSPGR) sequence (repetition
time [TR] = 7.5 ms, echo time [TE] = 3 ms, time to
inversion [TI] = 650 ms, matrix = 256 × 256, field of view
[FOV] = 240 mm), producing 216 contiguous images
(slice thickness = 1 mm) through the whole brain. We
also acquired resting-state functional scans comprising
a total of 150 echo-planar imaging (EPI) volumes with
the following parameters: TR = 2000 ms, TE = 30 ms,
matrix = 64 × 64, FOV = 240 mm, slice thickness = 3 mm,
40 continuous axial oblique slices (1 voxel = 3.75 ×
3.75 × 3.00 mm). During these image acquisitions, the
subjects were asked to close their eyes and instructed “not
to think of anything in particular.”
Image Analysis and Preprocessing
We used FSL (http://www.fmrib.ox.ac.uk)/AFNI(http://
afni.nimh.nih.gov/afni)-based script libraries from the
1000 Functional Connectomes Project (http://www.nitrc.
org/projects/fcon_1000)32 for preprocessing and a laboratory-developed script in the R statistical language for
additional analysis. Resting-state scans were preprocessed
using the scripts from the 1000 Functional Connectomes
Project (“fcon scripts”). Standard preprocessing included
removal of the first 4 “dummy” scans, motion correction,
and spatial smoothing (6-mm full width at half-maximum
Gaussian kernel). This was followed by standard registration and normalization to MNI152 space, with the
resulting transformation then applied to each individual’s
functional data set (12 parameter affine transformation).
The resulting time series were then filtered using high- and
low-pass filters (cutoff frequencies were 0.05 and 0.1 Hz,
respectively). Each individual’s 4D time series data were
regressed on 8 predictors: white matter (WM), cerebrospinal fluid, and 6 motion parameters. We did not regress out
the global signal because it would have shifted the correlation distribution to the middle and interfered with the
connectivity strength calculation described below. Given
the recent concerns raised by Power et al33 regarding the
effects of small motion on functional connectivity measures, we conducted careful motion analysis of our scans
(supplementary data and supplementary figures 1–4).
102

Regional Connectivity Strength
We computed regional mean time series in the restingstate fMRI data by using a set of predefined regions.34 In
their functional network study, Power et al demonstrated
that these regions (n = 264, diameter: 10 mm) are not only
functionally relevant but can eliminate artificial shortdistance correlations. In addition to these regions, we also
added caudate nucleus ROIs bilaterally. After obtaining
266 time series per subject, we decomposed these signals
with maximal overlap discrete wavelet transform35 similar
to the method of Lynall et al.26 We used the Daubechies
wavelet transform filter of length 4 and used the 0.060to 0.125-Hz scale wavelet coefficients for further analysis
(due to the preprocessing cutoff frequency at 0.1 Hz, in
our case, this covers the range of 0.06–0.1 Hz). We used
the R wavelet package to implement these calculations.36
We then estimated the correlation of these wavelet-transformed signals (wavelet coefficients) between each possible pair of regions. For each region i, we then averaged
the correlation coefficients that the i region had with all
the other j regions (ie, we averaged each row of the correlation matrix), and according to its usual name in the
connectivity literature, we named this metric “connectivity strength” (CS). Indeed, this reflects how strongly one
region is connected to other regions and what is often
referred to as ROI-based connectivity strength.
We also used complementary voxel-wise analyses to
compare these results with the ROI-based approach.
Using this approach, we computed correlations and
connectivity strength in all 181 144 voxels restricted to
a gray matter mask (FSL MNI atlas: MNI-maxprobthr25-2mm.nii.gz) in contrast to computing and averaging correlations in only 266 regions. We thus obtained a
complete map of connectivity strength in each individual.37 Further description of the ROI-based analyses and
voxel-based connectivity strength/correlation profiles is
provided in the supplementary data.
Statistical Analysis
All ROI analyses were conducted using SAS (version
9.1) and R (version 2.15.1) programs. We used repeatedmeasures analysis of variance (ANOVA) with a general linear model (ie, PROC GLM procedure with the
REPEATED statement). The between-subjects factor
was group (patients with SCZ, patients with BD, and
HCs). The within-subjects factor was region. Post hoc
tests were conducted using the SLICE option within
the LSMEANS (least-squares means) statement in SAS.
Raw P values obtained from the LSMEANS output were
adjusted for multiple testing using the ‘multtest’ package
in R. Because one of the main post hoc analyses involved
comparing the 3 groups for 266 regions, multiple testing
adjustments were done using the Benjamini-Hochberg
(BH) method controlling for the false discovery rate
(FDR). In the exploratory voxel-wise analysis, we used
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the SPM5 package (http://www.fil.ion.ucl.ac.uk/spm/)
to compare connectivity strength maps among groups
(P < .001 and P < .01, uncorrected), using all possible
contrasts (supplementary table 1).
We also used principal component analysis (PCA) to
evaluate how much the connectivity strength values vary
among regions across individuals by extracting out the
first principal component (PC; accounting for the majority
of variance). We thus conceptualized the extent to which
different ROIs would span a 266-dimensional space and,
with PCA, could find the subspace(s) responsible for a
majority of variance. This subspace also would reveal
how much the different ROIs “move together” in different
individuals. Connectivity strength was then investigated
in relationship to the clinical and cognitive measures
using Spearman Rank-order correlations, with P < .05.
We also used cluster analysis to determine whether the
“correlation profile” of a particular area (the correlation
coefficients between a particular area and all the other
areas) would be able to differentiate among groups of
subjects.
Results
There were no significant differences among groups
in distributions of age and sex (table 1). Connectivity
strength across the 266 brain regions for each group
in the ROI analysis is provided in figure 1. There was
a significant main effect of group (F = 237.94, degrees
of freedom [df] = 2, P < .0001); patients with SCZ had
greater disconnectivity overall compared to HCs (P <
.0001), and patients with BD had connectivity values
intermediate to and significantly different from those of
patients with SCZ (P < .0001) and HCs (P < .0001). The

group-by-region interaction was statistically significant
(F = 1.16, df = 530, P = .008) with post hoc analyses revealing that 6 of 266 unique regions survived FDR correction
for multiple comparisons (BH-adjusted P value < .05)
including the right (2 regions) and left thalamus, paracingulate gyrus, left caudate nucleus, and temporal occipital fusiform cortex/lingual gyrus. Subsequent analyses
indicated that compared with HCs, patients with SCZ
and patients with BD demonstrated significantly greater
(P < .05) disconnectivity in the paracingulate gyrus and
both right thalamic regions. In addition, patients with
SCZ demonstrated significantly greater disconnectivity
in the temporal occipital fusiform cortex, left caudate
nucleus, and left thalamus compared with the HCs. No
significant differences were evident between patients with
BD compared with patients with SCZ in any of these 6
regions. We did not find evidence for any systematic effect
of motion on the observed findings (supplementary data
and supplementary figures 1–4).
Complementary voxel-wise methods were largely consistent with the ROI approach (figure 2 and supplementary table 1). Specifically, we found that patients with SCZ
had lower global connectivity in the occipital fusiform,
cingulate gyrus, and cuneus. We also found differences
with the opposite sign in the caudate nucleus, hippocampal/parahippocampal gyrus, thalamus, and brainstem;
however, post hoc analysis indicated that in all cases,
HCs had negative correlations in these latter regions, so
that increased values in SCZ were closer to 0 and, thus,
should be interpreted as greater disconnectivity. As evident from supplementary table 1, these regions were also
identified when comparing BD patients and HCs, albeit
with lower statistical strength (and mostly at an exploratory level). Findings in BD are consistent, however, with

Fig. 1. Connectivity strength differences across the 266 regions of interest.
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Fig. 2. Voxel-wise connectivity strength. Note: When we compared HCs and patients (either SCZ or BD), we found areas where
connectivity strength was higher in patients (supplementary table 1), but post hoc analysis in these cases showed that the connectivity
strength was closer to 0 (ie, less negative). In a similar manner, the opposite contrasts also revealed areas where patients’ connectivity
strength was closer to 0, in very good agreement with the ROI-based calculations and figure 1. Open circles: outliers; data points outside
of the quartiles ±1.5 x interquartile range (standard in boxplot with R).

104

fMRI Connectivity Impairment in SCZ and BD

the ROI-based approach, viz, with the intermediate level
of global connectivity between HCs and SCZ patients
that BD patients express (see figure 2).
PCA revealed that different brain areas had high
covariance in connectivity strength (supplementary
figure 5). The first PC, which has the most variance in
PCA, was able to significantly differentiate between SCZ
and HC (F = 3.46, df = 66, P = .037; supplementary
figure 5A) and accounted for 49% of the variance.
Regions that accounted for most of the variance (regions
with the highest loading in the PCA analysis) included
parietotemporal, medial–frontal cortex (midline), insula,
and caudate nucleus bilaterally (supplementary figure 5B).
This also indicates that the individual scores of the first
PC account for general connectivity. The sign of PC #1
is arbitrary; in this case, more negative values represent
more “normal” connectivity, whereas more positive ones
indicate disconnectivity (consistent with supplementary
figure 5A).
At the time of the scan, we found significantly lower
antipsychotic use in BD patients compared with the SCZ
patients (t = −3.09, df = 25.1, P = .005) and lower use
of benztropine in the BD group than in the SCZ group
(Fisher’s exact test, P = .02). As expected, lithium was
used only in BD patients. We examined differences in
psychotropic medication usage between high- and lowconnectivity groups (table 2) but did not identify any
differences. We also used divided groups based on medication status to evaluate differences in global connectivity among groups (supplementary figure 6), but no such
differences were evident.
Cognitive and Clinical Correlates
MCCB raw data are presented in supplementary table
2. In all cases, BD patients had significantly better neurocognitive performance compared with SCZ patients.
Investigation of correlations between global connectivity (ie, PC #1 scores) and neurocognitive tasks indicated
that higher PC scores (ie, greater disconnectivity) were
associated with worse cognitive performance across
both patient groups (table 3); however, these effects were

not statistically significant in either patient group when
investigated separately. Seventeen of the 19 BD and 15
of the 18 SCZ patients completed BPRS assessments.
BPRS scores were significantly higher in SCZ patients
compared with BD patients (t = −3.05, df = 28.84, P =
.005). BPRS scores correlated significantly with global
connectivity (r = .37, df = 30, P = .035) such that lower
connectivity was associated with higher BPRS scores.
Subgroup analysis revealed that this relationship was,
however, not significant among the SCZ or BD groups
when examined separately. In addition, other measures
(ie, HRSD, CARS-M) more sensitive to the mood and/
or manic aspects of BD did not correlate significantly
with connectivity strength.
Analyses between individual regional connectivity and
the clinical and neuropsychological measures are provided in supplementary table 4. These analyses indicated
that greater disconnectivity in the caudate nucleus was
associated with higher BPRS scores among all patients.
Moreover, among all patients, greater disconnectivity in
the left caudate nucleus, temporal occipital fusiform cortex/lingual gyrus, and left thalamus was associated with
worse functioning on the Trailmaking Test–Part A.
Cluster Analysis
The cluster analysis indicated that regions showing group
differences in their average correlation (ie, connectivity
strength) were the ones that were the most useful in differentiating between patients and HCs. This data-driven
approach did not differentiate between BD and SCZ, but
it did distinguish between all patients in relation to HCs
based on their “correlation profile” (figure 3, correlation
between 2 sample t test and chi-square P values: r = .61,
t = 10.64, df = 196, P < .0001; supplementary table 3).
Discussion
We used resting-state fMRI and connectivity measures,
similar to those reported earlier in SCZ,24–26 to evaluate
the disconnectivity hypothesis of SCZ38–40 and its overlap
with BD. The main findings of our study indicate that

Table 2. Medication Status for Low- and High-Connectivity Groups
Class

High (n = 18) vs Low (n = 18) Connectivity

P Value, Fisher’s Exact Test

Antipsychotic
Benzodiazepines
Benztropine
Lithium
Antiepileptic drugs

14/18 vs 15/18
2/18 vs 5/18
4/18 vs 4/18
2/18 vs 2/18
5/18 vs 3/18

1.0
.4
1.0
1.0
.7

Note: All patients were divided into high and low global connectivity levels to determine whether medication status influenced the
results. For example, in the case of antipsychotics, 14 out of 18 patients with high-connectivity values vs 15 out of 18 patients with lowconnectivity values used antipsychotics. An inverse test was also performed, where we compared global connectivity among different
medication groups (see supplementary data).
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Table 3. Cognitive Measures

Cognitive Tests
MCCB (N = 30; 15 BD/15 SCZ)
Speed processing T score
Attention vigilance T score
Working memory T score
Verbal learning T score
Visual learning T score
Reasoning and problem solving T score
Social cognition T score
Overall composite T score
Verbal learning
HVLT (N = 32; 17 BD/15 SCZ)
  Correct words
  Delayed
  Recognition
  Total T score
Working memory
WMS-III (N = 32; 17 BD/15 SCZ)
  Raw
  T score
Letter–number span (N = 32; 17 BD/15 SCZ)
  Raw
  T score
Speed of processing
Trail making test A (N = 32; 17 BD/15 SCZ)
  Trail A error
   Trail A time (s)
  Trail A T score
BACS (N = 32; 17 BD/15 SCZ)
  Raw
  T score
Category fluency (N = 32; 17 BD/15 SCZ)
  Raw
  T score
Attention task (not part of MCCB)
Attention network (N = 31; 18 BD/13 SCZ)
   Alerting effect (ms)
   Orienting effect (ms)
   Conflict effect (ms)
   Mean RT correct trials (ms)
   Mean accuracy (%)

Post Hoc

BD vs SCZ
(P Values)

P (PAT)

R (PAT)

r (BD)

r (SCZ)

P (BD vs SCZ)

.28
.73
.57
.11
.49
.98
.007*
.19

.29
.74
.39
.07
.46
.67
.16
.27

−.20
−.06
−.16
−.34
−.14
.07
−.26
−.21

—
—
—
−.50
—
—
−.43
—

—
—
—
−.122
—
—
.05
—

—
—
—
.30
—
—
.21
—

.02*
.005*
.005*
.05*

.01*
.02*
.08
.18

−.45
−.43
−.33
−.25

−.61
−.54
−.50
−.29

−.15
−.26
−.01
−.11

.16
.40
.18
.65

.17
.26

.02*
.12

−.40
−.28

−.58
—

−.14
—

.18
—

.73
.80

.56
.68

−.11
−.08

—
—

—
—

—
—

.36
.53
.74

.21
.002*
.04*

.22
.51
−.36

.43
−.38

.56
−.39

.65
.97

.15
.36

.13
.24

−.27
−.21

.01*
.02*

.38
.55

−.16
−.11

−.04
−.03

−.06
.03

.97
.90

.69
.91
.07
.18
.18

.02*
.69
.009*
.15
.18

.40
.07
.46
.26
−.24

.26
—
.56
—
—

.57
—
.25
—
—

.35
—
.35
—
—

Note: BD, bipolar disorder; SCZ, schizophrenia; PAT, all patients together (BD and SCZ); MCCB, MATRICS Consensus Cognitive
Battery; HVLT, Hopkins Verbal Learning Test; WMS-III, Wechsler Memory Scale—3rd edition; BACS, Brief Assessment of Cognition
in Schizophrenia; RT, reaction time.
*P < .05. For all significant group differences, patients with BD performed better than patients with SCZ.

patients with SCZ had lower global connectivity compared with HCs and that patients with BD had global
connectivity values that were intermediate to and significantly different from SCZ patients and HCs (figure 1).
Although each patient group could be distinguished
from HCs in specific regions, no individual regions distinguished the patient groups. Moreover, the use of an
independent voxel-based approach yielded similar results
(figure 2), further supporting our findings.
It is difficult to compare our results to prior work in
BD given the paucity of studies; however, our results are
106

consistent with prior work in SCZ22,24–26,41 indicating that
patients had a profound and general decrease of connectivity (figure 1). Similarly, the use of cluster analysis could
not distinguish between SCZ and BD reliably, although
it could differentiate between HCs and all patients (figure 3). Recently, numerous genetic and epidemiologic
findings have questioned the strict dichotomy of these diseases3–12,42–46 and support the notion that they may be conceptualized as a continuum. Our findings could serve as a
neurobiological framework for better clarifying this continuum and may provide some explanation regarding why
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Fig. 3. Cluster analysis of correlation patterns. Note: In A and B, each row corresponds to an individual and each column to a region.
The color-coded values of the rows represent how well that particular region correlates with the caudate nucleus and fusiform gyrus,
respectively (supplementary table 3), which were chosen for illustration given that they demonstrated the most robust group differences
in connectivity. The rows of the matrix (ie, the individuals) are already ordered according to the result of the cluster analysis. In C, the
horizontal axis represents the strength that the connectivity of an area can separate HCs and patients (t test), while the vertical axis
represents the statistical strength that the cluster analysis (chi-square) yields in a certain area.

SCZ typically presents with more severe cognitive symptoms and worse prognosis. Moreover, our results may provide insight into the current debate regarding the nosology
of BD and SCZ and could potentially serve as an imaging
biomarker in the Research Domain Criteria.47,48
Investigation of the MCCB domains30,49–51 indicated
that “disconnectivity” was associated with cognitive
impairment. Specifically, higher PC scores (ie, greater
disconnectivity) were associated with worse cognitive
performance and higher BPRS scores across both patient
groups, but these relationships were not significant in
either patient group. Overall, our results suggest that
verbal learning, speed of processing, and attention tasks

were affected by the impaired global connectivity. These
domains are among the most affected cognitive functions
in SCZ and BD.52–58 It is important to note, however, that
all correlations were consistent with the hypothesis that
more impaired connectivity was associated with worse
functioning, suggesting that intact connectivity is a prerequisite of normal cognitive functioning. These findings
are also comparable with our previous study demonstrating an inverse relationship between WM integrity and
cognitive functions59 and with other functional connectivity findings.26
One of the overarching questions in the current connectivity literature of psychiatric illness is how to
107
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Fig. 4. Models to conceptualize disconnectivity.

conceptualize these different disorders (figure 4). Our
results are broadly consistent with model 3, where the
decrease in connectivity would be predicted to “move
together” across regions. This does not completely exclude
combinations with model 1 or 2, but the well-characterized decrease in connectivity among multiple areas (model
3) would make our method insensitive to these (model 1
or 2) other changes. One of the implications of model 3
is that we can meaningfully describe a single individual
with a generalized connectivity number, which would
describe the overall change in connectivity across regions.
Our results thus suggest that the first PC may be a good
choice for accomplishing this aim and could be examined
in relationship with cognition and clinical symptoms. We
acknowledge that a further possibility (not illustrated)
is that there could potentially be some degree of global
reduction in connectivity with superimposed “disease”
specific abnormalities in certain pathways.
There are several limitations to this study. The patient
sample sizes were small and the patients were receiving
antipsychotic medication, which could affect functional
connectivity.60 Moreover, antipsychotic use may be related
to WM abnormalities,61–64 which could conceivably lead
to functional connectivity changes.23 It should also be
acknowledged that patients with BD were being treated
with a lower antipsychotic dosage, which may have influenced global connectivity. We do not believe this is the
case, however, because other studies in first-episode SCZ
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patients23,25 found similar decreases in connectivity, and
we did not detect significant antipsychotic medication
effects in our study (table 2; supplementary figure 6).
Although functional connectivity studies in high-risk
and ultra-high-risk individuals have been somewhat contradictory, structural studies typically revealed decreased
connectivity among preselected brain regions.23 Due to
the small number of patients, the negative finding of the
direct comparison between SCZ and BD patients at the
ROI level should be interpreted with caution. It is conceivable that our methodology may have been less sensitive to detecting patient group differences at the ROI
level, where they may be more subtle compared with the
gross global connectivity measures. Finally, we acknowledge the lack of information regarding gray matter content within these specific ROIs, which could potentially
further inform the functional connectivity analyses.
In summary, our results further support the disconnectivity hypothesis in SCZ and extend this to BD. These
findings and their strong correlations with clinical and
cognitive measures could make global connectivity measures ideal candidates for use as biomarkers in future
imaging studies.
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